Suspension of trading
Exscientia plc Share Price
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.840 USD | +3.20% |
|
-.--% | - |
| 21/24/21 | Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index | CI |
| 20/24/20 | Recursion Pharmaceuticals, Exscientia Complete Business Combination | MT |
| Market Cap | 50Cr 67Cr 58Cr 54Cr 94Cr 6.4TCr 95Cr 638.62Cr 250.65Cr 3.2TCr 252.81Cr 247.24Cr 11TCr | P/E 2022 |
-4.55x | P/E 2023 | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 16Cr 21Cr 18Cr 17Cr 29Cr 1.99TCr 30Cr 198.95Cr 78Cr 997.66Cr 79Cr 77Cr 3.3TCr | EV / Sales 2022 |
1.9x | EV / Sales 2023 | 14.2x |
| Free-Float |
36.87% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +3.20% |
| 3 years | 3.8 |  | 8.37 |
| 5 years | 3.8 | | 30.38 |
| 10 years | 3.8 | | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 61 | 06/06/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/05/2022 | |
John Overington
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 63 | 28/09/2017 |
Robert Ghenchev
BRD | Director/Board Member | 43 | 01/05/2020 |
Elizabeth Crain
CHM | Chairman | 61 | 12/02/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.20% | -.--% | -.--% | -41.33% | 63Cr | |
| +0.90% | -2.33% | +0.68% | +13.87% | 4.86TCr | |
| +1.98% | +9.05% | +413.94% | +532.17% | 4.19TCr | |
| +3.44% | -4.65% | +28.34% | +8.81% | 3.89TCr | |
| +1.40% | +0.10% | +6.61% | +61.93% | 3.72TCr | |
| +2.42% | +5.72% | +12.38% | +44.79% | 3.07TCr | |
| -0.16% | -3.11% | - | - | 1.61TCr | |
| +2.20% | +0.48% | +34.71% | +127.15% | 1.64TCr | |
| +1.25% | +1.52% | +4.62% | +18.26% | 1.4TCr | |
| +4.25% | -8.23% | -1.49% | -35.46% | 1.26TCr | |
| Average | +2.09% | -0.70% | +55.53% | +81.13% | 2.57TCr | |
| Weighted average by Cap. | +1.92% | -0.12% | +81.94% | +119.91% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 2.72Cr 3.67Cr 3.18Cr 2.96Cr 5.14Cr 348.6Cr 5.2Cr 35Cr 14Cr 174.42Cr 14Cr 13Cr 577.67Cr | 2.01Cr 2.7Cr 2.34Cr 2.18Cr 3.79Cr 257.12Cr 3.83Cr 26Cr 10Cr 128.65Cr 10Cr 9.93Cr 426.07Cr |
| Net income | -12Cr -16Cr -14Cr -13Cr -22Cr -1.52TCr -23Cr -151.69Cr -60Cr -760.7Cr -60Cr -59Cr -2.52TCr | -15Cr -20Cr -17Cr -16Cr -28Cr -1.87TCr -28Cr -186.49Cr -73Cr -935.2Cr -74Cr -72Cr -3.1TCr |
| Net Debt | -49Cr -66Cr -57Cr -53Cr -93Cr -6.3TCr -94Cr -628.5Cr -246.68Cr -3.15TCr -248.81Cr -243.32Cr -10TCr | -34Cr -46Cr -40Cr -37Cr -65Cr -4.41TCr -66Cr -439.68Cr -172.57Cr -2.2TCr -174.06Cr -170.22Cr -7.3TCr |
Employees
483
- Stock Market
- Stocks
- EXAI Stock
Select your edition
All financial news and data tailored to specific country editions
